February 25, 2025

Sigyn Therapeutics to be Featured in Fireside Chat With Zacks Healthcare Analyst

The Exclusive Event Kicks-Off Tomorrow February 26th at 4pm Eastern

SAN DIEGO - February 25, 2025 (NEWMEDIAWIRE) - Sigyn Therapeutics, Inc. ("Sigyn" or the "Company") (OTCQB: SIGY), a developer of next-generation blood purification devices to treat cancer and life-threatening infectious disease disorders, disclosed today that Company CEO, Jim Joyce, will participate in a Fireside Chat tomorrow with Zacks Senior Healthcare Analyst, John Vandermosten. Zacks is a leading investment research firm focusing on stock research, analysis and recommendations. This exclusive event is being hosted by Force Family Office, the largest network of family offices in the United States with a substantial and growing presence internationally.

The Fireside Chat will review the emergence of blood purification therapies to address life-threatening infectious disease conditions that are beyond the reach of drugs and additionally will discuss the development of devices to synergistically optimize the benefit of leading drugs to treat cancer.

Event Details

Date: February 26th

Time: 4pm Eastern (1pm Pacific)

Registration: https://forcefamilyoffice.com/events/healthcare/sigyn-therapeutics-coming-february-26-2025/

Force Family Office Event Description

Healthcare is driven by innovation. New discoveries, technologies, applications, molecules, devices, and formulations are at the heart of an industry that never stands still. Which are the experts watching? One of those is Sigyn Therapy, a blood purification therapy with applications in infectious disease, oncology, dialysis and organ transplantation. Register now to join this Fireside Chat with Zacks Senior Healthcare Analyst, John Vandermosten, and Jim Joyce, CEO of Sigyn Therapeutics, for a discussion of innovations on the horizon that will be creating value in the healthcare sector.

About Sigyn Therapeutics(TM)

Sigyn Therapeutics is developing next-generation blood purification therapies to address cancer and life-threatening infectious disease disorders that are not treatable with drugs. The Company's lead product candidate, Sigyn Therapy(TM) has been demonstrated to reduce the presence of viral pathogens, bacterial toxins, and pro-inflammatory cytokines from human blood plasma. Based on these capabilities, Sigyn Therapy(TM) is a candidate to treat life-threatening viral pathogens, antibiotic-resistant bacterial infections, endotoxemia, and sepsis, which is the leading cause of death in U.S. hospitals. The clinical protocol of first-in-human studies incorporates Sigyn Therapy with regularly scheduled dialysis treatments to address endotoxemia and concurrent inflammation, which are highly prevalent disorders that shorten the lives of end-stage renal disease (ESRD) patients. Extending the lives of those with ESRD could significantly impact dialysis industry revenues.

The Company's oncology pipeline is comprised of ImmunePrep(TM), a platform to enhance the delivery of immunotherapeutic antibodies; ChemoPrep(TM) to improve the delivery of chemotherapeutic agents; and ChemoPure(TM) to reduce chemotherapy toxicity. If successfully advanced, the Company's therapies offer to provide strategic value to the dialysis and biopharmaceutical industry.

To learn more about Sigyn Therapeutics, visit: www.SigynTherapeutics.com

CONTACTS:
Sigyn Therapeutics, Inc.
Johan Louw
Senior Vice President of Strategic Programs
281.660.1815
jlouw@SigynTherapeutics.com

Jim Joyce
CEO, Inventor
Email: jj@SigynTherapeutics.com

Cautionary Note Regarding Forward-Looking Statements

This information in this press release contains forward-looking statements of Sigyn Therapeutics, Inc. ("Sigyn") that involve substantial risks and uncertainties. All statements contained in this summary are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as "may," "believe," "anticipate," "expect," "intend," "plan," "project," "will," "projections," "estimate," "potentially" or similar expressions constitute forward-looking statements. Such forward-looking statements are subject to significant risks and uncertainties and actual results may differ materially from the results anticipated in the forward-looking statements. These forward-looking statements are based upon Sigyn's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Factors that may contribute to such differences may include, without limitation, the Company's ability to clinically advance Sigyn Therapy in human studies required for market clearance, the Company's ability to manufacture Sigyn Therapy, the Company's ability to raise capital resources, and other potential risks. The foregoing list of risks and uncertainties is illustrative but is not exhaustive. Additional factors that could cause results to differ materially from those anticipated in forward-looking statements can be found under the caption "Risk Factors" in the Company's Annual Report on Form 10-K, and in the Company's other filings with the Securities and Exchange Commission, including its quarterly Reports on Form 10-Q. All forward-looking statements contained in this report speak only as of the date on which they were made. Except as may be required by law, the Company does not intend, nor does it undertake any duty, to update this information to reflect future events or circumstances.